Printer Friendly

United States : Q BioMed Announces Attendance at Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.

Q BioMed Inc., and executives from its advanced technology partner Bio-Nucleonics Inc. will attend the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June 10 14, 2017. The SNMMI annual meeting brings together leading nuclear medicine physicians, scientists and technologists from leading medical and academic centers.

The meeting provides an ideal location to meet with collaborators, vendors and partners working on the recently announced commercialization of Strontium-89 Chloride (Sr89). Sr89 Injection USP is a non-opioid analgesic indicated for the relief of bone pain in patients with painful skeletal cancer metastases.

Approximately 70% of patients with advanced breast and prostate cancer metastases will develop bone metastases, an extremely painful condition. Bone metastases occur in most tumor types but are most prevalent in cancers of the breast, prostate, and lung. These bone lesions can cause serious skeletal complications, including spinal cord or nerve root compression, hypercalcemia of malignancy, pathologic fractures, and severe bone pain which can significantly compromise quality of life and may negatively affect survival. Palliation of pain, prevention of skeletal complications, and maintenance of quality of life are the primary objectives in managing patients with metastatic bone disease.

AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be used in combination with or to reduce the need for opiate based drugs, as well as in combination with cancer therapeutic drugs. After administration, pain relief can occur in as little as one to two weeks and can last several months, when another dose can be administered with minimal side effects. Clinical studies have demonstrated that for many, the combination of alternating weekly chemohormonal therapies with Sr89 demonstrated a prolonged and progression-free survival.

[c] 2017 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jun 10, 2017
Previous Article:China : Dahua Technology Launches a Thermal Camera Truly for Commercial Market.
Next Article:Canada : Delta State University finds a more Robust Course Evaluation System in Blue.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters